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Abstract: Improved micropollutant (MP) biotransformation during biological wastewater treatment has
been associated with high ammonia oxidation activities, suggesting co-metabolic biotransformation by
ammonia oxidizing bacteria as an underlying mechanism. The goal of this study was to clarify the
contribution of ammonia oxidizing bacteria to increased MP degradation in nitrifying activated sludge
(NAS) communities using a series of inhibition experiments. To this end, we treated a NAS community
with two different ammonia oxidation inhibitors, namely octyne (OCT), a mechanistic inhibitor that
covalently binds to ammonia monooxygenases, and allylthiourea (ATU), a copper chelator that depletes
copper ions from the active center of ammonia monooxygenases. We investigated the biotransformation
of 79 structurally different MPs by the inhibitor-treated and untreated sludge communities. Fifty-five
compounds exhibited over 20% removal in the untreated control after a 46 h-incubation. Of these,
31 compounds were significantly inhibited by either ATU and/or OCT. For 17 of the 31 MPs, the
inhibition by ATU at 46 h was substantially higher than by OCT despite the full inhibition of ammonia
oxidation by both inhibitors. This was particularly the case for almost all thioether and phenylurea
compounds tested, suggesting that in nitrifying activated sludge communities, ATU does not exclusively
act as an inhibitor of bacterial ammonia oxidation. Rather, ATU also inhibited enzymes contributing
to MP biotransformation but not to bulk ammonia oxidation. Thus, inhibition studies with ATU tend
to overestimate the contribution of ammonia-oxidizing bacteria to MP biotransformation in nitrifying
activated sludge communities. Biolog tests revealed only minor effects of ATU on the heterotrophic
respiration of common organic substrates by the sludge community, suggesting that ATU did not affect
enzymes that were essential in energy conservation and central metabolism of heterotrophs. By comparing
ATU- and OCT-treated samples, as well as before and after ammonia oxidation was recovered in OCT-
treated samples, we were able to demonstrate that ammonia-oxidizing bacteria were highly involved in
the biotransformation of four compounds: asulam, clomazone, monuron and trimethoprim.
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Fig. S3. Biotransformation curves of the 55 MPs with relative removals > 20% (x-axis: Time (h); 
y-axis: compound concentration (ng/L); black: Pos. Ctrl; blue: OCT; red: ATU; round, triangle 
and diamond symbols represent the three replicates under each condition.  
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Fig. S7. The detection of N4-acetyl conjugation products of the five investigated sulfonamide 
antibiotics (Note: due to the lack of the reference compound of N4-acetyl sulfapyridine, only 
integrated peak areas at [M+H] = 292.0750 are given; for all the other four compounds, the 
corresponding reference compounds were used for quantification). 
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Table S1 List of MPs and internal standards used for LC-MS/MS 
MP Ionizatio
n mode 
m/z InSTD Structure Classification 
Acesulfam negative 161.9867 Acesulfam-D4 
 
others 
Acetamiprid positive 223.0745 Dimethoate-D6 
 
amidine	
Alachlor positive 270.1255 Alachlor-D13 
 
chloroacetanilide 
Amisulpride positive 370.1795 Amisulpride-D5 
 
others	
Asulam positive 231.0434 Atenolol-acid D5 
 
others	
Atenolol positive 267.1703 Atenolol-D7 
 
primary amide 
Atrazine positive 216.1011 Atrazine-D5 
 
triazine 
Azoxystrobin positive 404.1241 Bezafibrate-D4 
 
ester 
Bezafibrate positive 362.1154 Bezafibrate-D4 
 
secondary amide 
Bicalutamide negative 429.0538  
 
secondary	
amide	
Boscalid positive 343.0399 Bezafibrate-D4 
 
secondary amide 
Bromoxynil negative 273.8509  
 
Others	
Capecitabin positive 360.1565 Atrazine-D5 
 
Carbamate 
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Carbendazim positive 192.0768 Carbendazim-D4 
 
Carbamate 
Carbetamide negative 235.1088  
 
Carbamate 
Chlortoluron positive 213.0789 Chlortoluron-D6 
 
phenylurea	
Citalopram positive 325.1711 Citalopram-D6 
 
Others	
Clomazone positive 240.0786 Naproxen-D3 
 
others 
Crotamiton positive 204.1383 Dimethenamide-
D3 
 
Tertiary amide 
Cyromazine positive 167.1040 Morphine-D3 
 
Triazine	
Deprenyl positive 188.1439 Diazinon-D10 
 
Amine 
Diazepam positive 285.0789 Diazepam-D5 
 
Tertiary amide 
Dicamba negative 218.9621 Dicamba-D3 
 
Ether	
Diclofenac positive 296.0240 Diclofenac-D4 
 
Others	
Dimefuron positive 339.1218 Diuron-D6 
 
Phenylurea	
Dimethenamide positive 276.0820 Dimethenamid-
D3 
 
Chloroacetanilid
e	
Diuron positive 233.0243 Diuron-D6 
 
Phenylurea	
Ethofumesat positive 287.0948 Bezafibrate-D4 
 
Others 
Fenhexamide positive 302.0709 Terbutylazine-D5 
 
Secondary amide 
Fenoxycarb positive 302.1387 Terbutylazine-D5 
 
Carbamate	
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Fipronil negative 434.9314 
 
 
 
Others	
Flufenacete positive 364.0737 Terbutylazine-D5 
 
Chloroacetanilid
e	
	
Fluoxetine positive 310.1413 Fluoxetine-D5 
 
Ether	
Furosemide negative 329.0004  
 
Others 
Hydrochlorothiazid
e 
negative 295.9572  
 
Amine 
Ibuprofen positive 207.1380 Ibuprofen-D3 
 
Others 
Imidacloprid positive 256.0596 Imidacloprid D4 
 
Others 
Indomethacin positive 358.0841 Indomethacin-D4 
 
Others 
Iprovalicarb positive 321.2173 Terbutylazine-D5 
 
Carbamate	
Irgarol positive 254.1434 Irgarol-D9 
 
Thioether	
Isoproturon positive 207.1491 Isoproturon-D6 
 
Phenylurea 
Ketoprofen positive 255.1016 Atrazine-D5 
 
Others 
Kresoxim-methyl positive 314.1387 Diclofenac-D4 
 
Ester 
 
Levetiracetam positive 171.1128 Levetiracetam-
D3 
 
Primary amide 
Lovastatin positive 405.2636 Fenofibrate-D6 
 
Ester 
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Mecoprop negative 213.0324 Mecoprop-D6 
 
Ether	
Metalaxyl positive 280.1543 Bicalutamide-D4 
 
Ester	
Metolachlor positive 284.1412 Metolachlor-D6 
 
chloroacetanilid
e	
Metoxuron positive 229.0738 Carbamazepin-
10-11-epoxid- 
13C- D2  
Phenylurea	
Monuron positive 199.0633 Atrazine-D5 
 
Phenylurea	
N,N-dimethyl-4-
chlorobenzamide 
(MMcIB) 
positive 184.0524 Clotrimazole-D5 
 
Tertiary	amide	
Napropamide positive 272.1645 Terbutylazine-D5 
 
Tertiary	amide	
Naproxen positive 231.1016 Naproxen-d3 
 
Others 
N-butyl-N-ethyl-4-
chlorobenzamide 
(BEcIB) 
positive 240.1150 Terbutylazine-D5 
 
Tertiary amide 
N-N-diethyl-3-
methylbenzamide 
(DEET) 
positive 192.1383 DEET-D10 
 
Tertiary	amide	
Oseltamivir positive 313.2122 Clopidogrel-(+/-)-
D4 
 
Ester 
Pargyline positive 160.1126 Diazinon-D10 
 
Amine	
Perindopril positive 369.2388 Atomoxetine-D3 
 
Others 
Pheniramine positive 241.1699 Levetiracetam-
D3 
 
amine	
Propachlor positive 212.0837 Atrazine-D5 
 
Chloroacetanilide 
Propranolol positive 260.1645 Citalopram-D6 
 
Others	
Propyzamide positive 256.0291 Terbutylazine-D5 
 
Secondary amide 
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Ranitidine positive 315.1485 Ranitidine-D6 
 
Thioether 
Rufinamide positive 239.0739 Clothianidine-D3 
 
Primary amide 
Simeton positive 198.1349 Sulfamethoxazol
e-D4 
 
Triazine	
Sulfadiazine positive 251.0597 Sulfadiazine-D4 
 
Sulfonamide 
Sulfamethazine positive 279.0910 Sulfamethazine-
13C6 
 
Sulfonamide	
Sulfamethoxazole positive 254.0594 Sulfamethoxazol
e-D4 
 
Sulfonamide	
Sulfapyridine positive 250.0645 Sulfapyridine-D4 
 
Sulfonamide	
Sulfathiazole positive 256.0209 Sulfathiazole-D4 
 
Sulfonamide	
Tebufenozide positive 353.2224 Terbutylazine-D5 
 
Secondary amide 
Tebutam positive 234.1852 Tebutam-D4 
 
Tertiary amide 
Terbutryn positive 242.1434 Chlortoluron-D6 
 
Thioether 
Terbutylazine positive 230.1167 Terbutylazine-D5 
 
Triazine 
Thiacloprid positive 253.0309 Morphine-D3 
 
Amidine 
Ticlopidine positive 264.0608 Pirimicarb D6 
 
Others 
Trimethoprim positive 291.1452 Trimethoprim-D9 
 
Others 
Trinexapac-ethyl positive 253.1071 Diuron-D6 
 
Ester 
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Valsartan positive 436.2343 Valsartan-13C5-
15N 
 
Tertiary amide 
 
 
 
Table S2 Ammonia utilization rate (AUR) in inhibitor-treated and untreated control reactors  
	
Reactor 0h-AUR (mgL-1h-1) 70h-AUR (mgL-1h-1) 
Ctrl 10 6.15 
ATU 0 0 
OCT 0 0.7 
	
